We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding ...

Interactive Chart for Sarepta Therapeutics, Inc. (SRPT), analyze all the data with a huge range of indicators.

Investing.com - 摩根大通将Sarepta Therapeutics (NASDAQ:SRPT)的目标价从30.00美元下调至28.00美元，同时维持对该股的"增持"评级。根据InvestingPro数据，该股在过去一年下跌了87%，分析师目标价范围从10美元到110美元不等。 该公司指出，相对于公司商业产品组合的长期潜力，当前价位存在"估值脱节"现象。 Sarepta的产品组合包括 ...

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for ...

Find out the direct holders, institutional holders and mutual fund holders for Sarepta Therapeutics, Inc. (SRPT).

Review which funds and institutions currently hold Sarepta Therapeutics Inc (SRPT:XNAS) stock for ownership information.

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focu ...

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of ...